Transamerica Financial Advisors Inc. Acquires Shares of 4,760 Sanofi (NASDAQ:SNY)

Transamerica Financial Advisors Inc. acquired a new stake in Sanofi (NASDAQ:SNY) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,760 shares of the company’s stock, valued at approximately $275,000.

Other institutional investors have also recently bought and sold shares of the company. POM Investment Strategies LLC bought a new stake in shares of Sanofi during the 2nd quarter worth approximately $25,000. Northwest Investment Counselors LLC bought a new stake in shares of Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners lifted its holdings in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp bought a new stake in shares of Sanofi during the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC lifted its holdings in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $48.28 on Wednesday. The company has a market cap of $122.53 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a 50 day simple moving average of $53.35 and a 200 day simple moving average of $52.17. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on SNY shares. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.